A phase Ib clinical trial published in Nature Communications reported early efficacy and feasibility signals for a personalized neoantigen-pulsed, autologous dendritic cell vaccine in patients newly diagnosed with glioblastoma. The investigational approach delivers individualized tumor neoantigens to patient-specific dendritic cells as an immunotherapy strategy. The study adds clinical momentum to personalized dendritic cell platforms, where manufacturing and turnaround time have historically been key bottlenecks. By focusing on newly diagnosed patients, the trial also targets a window where immunotherapy may better shape tumor–immune interactions before major disease progression. While phase Ib results are not definitive for survival endpoints, the publication strengthens the evidence base for neoantigen-guided cellular immunotherapy in aggressive brain tumors and informs how next-stage trials may refine dose and scheduling.